The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Prime Medicine Inc (NASDAQ: PRME) closed the day trading at $3.74 down -3.61% from the previous closing price of $3.88. In other words, the price has decreased by -$3.61 from its previous closing price. On the day, 2.3 million shares were traded. PRME stock price reached its highest trading level at $4.12 during the session, while it also had its lowest trading level at $3.72.
Ratios:
For a better understanding of PRME, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.61 and its Current Ratio is at 6.61. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.68.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’25 when GV 2021 GP, L.L.C. bought 1,500,000 shares for $3.30 per share. The transaction valued at 4,950,000 led to the insider holds 3,262,440 shares of the business.
NELSEN ROBERT bought 3,030,300 shares of PRME for $9,999,990 on Aug 01 ’25. The Director now owns 6,230,300 shares after completing the transaction at $3.30 per share. On Aug 01 ’25, another insider, ARCH Venture Partners XII, LLC, who serves as the 10% Owner of the company, bought 3,030,300 shares for $3.30 each. As a result, the insider paid 9,999,990 and bolstered with 6,230,300 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRME now has a Market Capitalization of 675109824 and an Enterprise Value of 566970560. For the stock, the TTM Price-to-Sale (P/S) ratio is 112.89 while its Price-to-Book (P/B) ratio in mrq is 4.17. Its current Enterprise Value per Revenue stands at 94.859 whereas that against EBITDA is -2.881.
Stock Price History:
The Beta on a monthly basis for PRME is 2.67, which has changed by 0.39068103 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, PRME has reached a high of $6.94, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -15.83%, while the 200-Day Moving Average is calculated to be 15.79%.
Shares Statistics:
Over the past 3-months, PRME traded about 3.94M shares per day on average, while over the past 10 days, PRME traded about 3472060 shares per day. A total of 180.31M shares are outstanding, with a floating share count of 93.82M. Insiders hold about 48.03% of the company’s shares, while institutions hold 38.15% stake in the company. Shares short for PRME as of 1764288000 were 19673466 with a Short Ratio of 4.99, compared to 1761868800 on 18214907. Therefore, it implies a Short% of Shares Outstanding of 19673466 and a Short% of Float of 17.78.
Earnings Estimates
The stock of Prime Medicine Inc (PRME) is currently in the spotlight, with 11.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.11 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.09 and -$1.41 for the fiscal current year, implying an average EPS of -$1.27. EPS for the following year is -$0.9, with 10.0 analysts recommending between -$0.56 and -$1.39.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for PRME’s current fiscal year. The highest revenue estimate was $13.79M, while the lowest revenue estimate was $3.79M, resulting in an average revenue estimate of $5.7M. In the same quarter a year ago, actual revenue was $2.98M
